PT  - JOURNAL ARTICLE
AU  - Paul J. Joudrey
AU  - Marynia Kolak
AU  - Qinyun Lin
AU  - Susan Paykin
AU  - Vidal Anguiano, Jr
AU  - Emily A. Wang
TI  - Community social vulnerability and access to medications for opioid use disorder within the continental US: A cross-sectional study
AID  - 10.1101/2021.09.30.21264351
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.30.21264351
4099  - http://medrxiv.org/content/early/2021/10/01/2021.09.30.21264351.short
4100  - http://medrxiv.org/content/early/2021/10/01/2021.09.30.21264351.full
AB  - The COVID-19 pandemic, like past natural disasters, was associated with significant disruptions in medications for opioid use disorder services and increased opioid overdose and mortality. We examined the association between community vulnerability to disasters and pandemics and geographic access to each of the three medications for opioid use disorder within the continental US and if this association was impacted by urban, suburban, or rural classification. We found communities with greater vulnerability did not have greater geographic access to medications for opioid use disorder and the mismatch between vulnerability and medication access was greatest in suburban communities. Rural communities had poor geographic access to all three medications regardless of vulnerability. Future disaster preparedness planning should include anticipation of access to medications for opioid use disorder and better match the location of services to communities with greater vulnerability to prevent inequities in opioid overdose deaths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this publication was provided by grant number 5K12DA033312 (P.J.J.), L30 DA052056 (P.J.J.), from the National Institute on Drug Abuse, a component of the National Institutes of Health. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University IRB determined this study was not human subjects research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request.